Professor McGorry has been part of a team researching pre- and early-psychosis, and his work in the latter helped secure a massive $222.4 million Commonwealth funding injection for Early Psychosis Prevention and Intervention Centres across Australia. They have found symptoms such as having some delusions or disorganised speech and thought can predict psychosis. But he believes young people at risk of psychosis are already over-medicated and inclusion in the manual could worsen the problem. "I think it’s a valid point to be concerned about the harms particularly in places like America," he said. "I think probably I have given a bit more weight to that argument now".He said 27 per cent of patients in his ultra-high risk clinics had to be taken off anti-psychotic medications prescribed by GPs. Professor McGorry has been heavily criticised for his work in early psychosis by doctors who believe it will lead to overmedication. "I certainly didn’t push for [pre-psychosis] to be included although I got panned as if that was what I was trying to do," he said. ”I just didn’t want 15 years of progress to be lost"…
Professor McGorry said it was his focus on developing staging models in psychiatry, similar to those seen in other areas of medicine such as cancer treatment where an illness is graded from symptoms needing investigation through to stages of the disease varying in seriousness, that had led him to decide the DSM listing was not helpful. "We need a more radical change to the diagnostic approach which allows people to get help when they really need it but also ensures risky treatments that cause harm wont get used."
Treatment centres such as Headspace, which allowed for non-drug treatments such as counselling or employment help, could provide the first step in such a system, without needing a DSM diagnosis to be attached to the people who used them. "It’s quite a legitimate debate, what the boundaries of mental illness are," he said. "We want to provide help, but we don’t want to turn everyone into a brain disease."
And he might do well to call his friend Ian Hickie and pass on a lesson in humility. Hickie’s paranoid campaign against Lancet Editor Richard Horton demanding retraction of "edgy tweets" is sounding increasingly bizarre [how would you retract a tweet anyway?]. From my perspective, the fact that so many people jumped on Hickie’s article about Agomelatine that quickly is a patch of blue in an overcast sky – that publications that bespeak conflict of interest are just not going to be tolerated anymore as they have been in the all too recent past.
Allen Frances, the chairman of the task force that created the current DSM and a critic of the proposals for the new manual, proposal to include pre-psychosis, currently called attenuated psychosis, in the manual that inspired his campaign. "It was a very specific moment, it was in May of 2009," he said. "I realised the ark DSM5 was taking would be so far off the mark that it would be irresponsible not to say anything."
Speaking of humility, now would be a really good time for the DSM-5 Task Force to develop some humility itself. Barreling ahead right now is a really bad idea on any number of counts. If reason were to prevail, they’d take a mid-course correction stop, and rethink their deadlines to make this the middle – not close to the end.
Question:
Will McGorry now give back the millions of dollars given to him by the Australian government?
This really make me curious. Why did McGorry apparently change his mind?
But I am also curious about why you think McGorry has a valid idea. As far as I understand it McGorry’s idea is not early intervention, but early intervention with antipsychotics. I can’t see that there is any evidence that this idea is valid. Rather the critic has been that early use of antipsychotics may harm unnecessary without any actual benefit compared to other early interventions. Am I missing something?
The valid idea to me is the quest to identify patients who will develop Schizophrenia before they become psychotic. I’ve been as vocal about not using medications preemptively as any, particularly with the criteria as shaky as now. But I think the idea of preemptively identifying the cases and trying non-medication interventions is sound. McGorry has done this as well, but then got all excited about medication. I’ve been impressed with the the British group’s approach:
C’mon Mickey, you’ve just tantalisingly dangled the possibility of a Twitter presence in front of us in your last line. Are we going to see @1boringoldman sometime soon?
@Mickey: Thanks, yes the idea of identifying them early to help them is of course very good. I have no doubt that has been McGorry’s intention, but I thought he did not want to try medication-free alternatives.
The problem I see even with short medication is that the figures actually seems to indicate that even short term use can harm. (See CATIE for example, but don’t forget to keep the results from the monkeys in Lewis laboratory in mind at the same time. There are also indications that some gene variants can be more vulnerable – though I do not remember where at the moment.)
In addition to the results above the results from Amminger 2010 looks promising. And again: The result was a sixfold decrease in psychosis in the following year for those given omega-3 for a short period (about on month). For some reason they stated it very different so you may be fooled when reading the abstract:
Amminger, G. P., Schafer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., et al. (2010). Long-Chain {omega}-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial. Arch Gen Psychiatry, 67(2), 146-154.
http://dx.doi.org/10.1001/archgenpsychiatry.2009.192
http://www.ncbi.nlm.nih.gov/pubmed/20124114
Important is also that in the 2010 trial the patients were neuroleptic naive. In the 2007 trial by Amminger they were not – and the results are quite different!
Maybe McGorry has seen this too? I am surprised to not see very much about those two trials.